A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 750-755

  Samlowski, Wolfram E ^a   Petersen, Ryan ^a   Cuzzocrea, Salvatore ^d   Macarthur, Heather ^b   Burton, Damali ^a   McGregor, John R ^a   Salvemini, Daniela ^c  

^a UNIVERSITY OF UTAH   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MetaPhore Pharmaceuticals   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CATECHOLAMINE; INTERLEUKIN 2; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER REGRESSION; CANCER SURVIVAL; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOTENSION; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; MELANOMA; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; SUPEROXIDE DISMUTASE; SURVIVAL RATE;

ANIMALIA;

EID: 0038714286     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm874     Document Type: Article

References (44)

1. Mertelsmann, R. & Welte, K. Human interleukin-2 molecular biology, physiology and clinical possibilities. Immunobiology 172, 400-419 (1986).
2. Weiss, A. T lymphocyte activation, in Fundamental Immunology (ed. Paul, W.E.) 467-504 (Raven, New York, 1993).
3. Lanier, L.L. et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480-4486 (1986).
4. Grimm, E.A. & Wilson, D.J. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol. 94, 568-578 (1985).
5. Harker, W.G. et al. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Cancer Res. 50, 5931-5936 (1990).
6. Fisher, R.I. et al. High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J. 3, S70-S72 (1997).
7. Siegel, J.P. & Puri, R.K. Interleukin-2 toxicity. J. Clin. Oncol. 9, 694-704 (1991).
8. Margolin, K.A. et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J. Clin. Oncol. 7, 486-498 (1989).
9. Ognibene, F.P. et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94, 750-754 (1988).
10. Ettinghausen, S.E., Puri, R.K. & Rosenberg, S.A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst. 80, 177-188 (1988).
11. Mann, H., Ward, J.H. & Samlowski, W.E. Vascular Jeak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology 176, 191-194 (1990).
12. Lee, R.E. et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7, 7-20 (1989).
13. Gaynor, E.R. et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 109, 953-958 (1988).
14. Macarthur, H. et al. Inactivation of catecholamines by superoxide gives new insight into the pathogenesis of septic shock. Proc. Natl. Acad. Sci. USA 97, 9753-9758 (2000).
15. Graham, D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and quinones. Mol. Pharmacol. 14, 633-643 (1978).
16. Bindolini, A., Rigobello, M.P. & Delbi, D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 13, 391-395 (1992).
17. Suzuki, K. et al. Priming effect of recombinant human interleukin-2 and recombinant human interferon-γ on human neutrophil superoxide production, Arzneimittelforschung 40, 1176-1179 (1990).
18. Faggioni, R. et al. Mechanisms of interleukin-2-induced hydrothorax in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J. Immunother. Emphasis Tumor Immunol. 15, 194-201 (1994).
19. Rosenberg, S.A. et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169-1188 (1985).
20. Ettinghausen, S.E. & Rosenberg, S.A. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 46, 2784-2792 (1986).
21. Samlowski, W.E. Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity. in Nitric Oxide and Inflammation (eds. Salvemini, D., Billiar, T.R. & Vodovotz, Y.) 249-272 (Birkhäuser Publishing, Basel, 2001).
22. Hellsstrand, K. et al. Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest. 57, 193-202 (1997).
23. Yim, C.-Y. et al. Nitric oxide synthesis contributes to IL-2 induced antitumor responses against intraperitoneal Meth A tumor. J. Immunol. 155, 4382-4390 (1995).
24. Salvemini, D. et al. Synzymes: potent non-peptidic agents against superoxide-driven tissue injury. Science 286, 304-306 (1999).
25. Becker, J.C. et al. T-cell mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183, 2361-2366 (1996).
26. Brunda, M.J., Bellantoni, D. & Sulich, V. In vivo anti-tumor activity of combinations of interferon-α and interleukin-2 in a murine model: Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 40, 365-371 (1987).
27. Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
28. Hellstrand, K., Asea, A. & Hermodsson, S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes and natural killer cells. J. Leukocyte Biol. 55, 392-397 (1994).
29. Kono, K. et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cells and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26, 1308-1313 (1996).
30. Dohlsten, M. et al. Synergistic action of γ-interferon and catalase to reverse the suppressive effects of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand. J. Immunol. 24, 49-58 (1986).
31. Linden, O. et al. Catalase and lipopolysaccharide enhanced proliferation in the rat mixed lymphocyte reaction. Scand. J. Immunol. 26, 223-228 (1987).
32. Uotila, P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43, 1-9 (1996).
33. Seaman, W.E. et al. Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirements for reactive metabolites of oxygen. J. Clin. Invest. 69, 876-888 (1982).
34. Seaman, W.E. et al. Natural killing of tumor cells by human peripheral blood cells: Suppression of killing in vitro by tumor-promoting phorbol diesters. J. Clin. Invest. 67, 1324-1333 (1981).
35. Hellstrand, K. & Hermodsson, S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol. 92, 379-389 (1990).
36. Hellstrand, K. & Hermodsson, S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J. Immunol. 139, 869-875 (1987).
37. Hellstrand, K. & Hermodsson, S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J. Immunol. 137, 656-660 (1986).
38. Johnson, R.B. Jr., Godzik, C.A. & Cohn, Z.A. Increased superoxide production by immunologically activated and chemically elicited macrophages. J. Exp. Med. 148, 115-127 (1978).
39. Pabst, M.J. & Johnston, R.B. Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J. Exp. Med. 151, 101-114 (1980).
40. Moulian, N. et al. In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood 97, 3521-3530 (2001).
41. Hansson, M. et al. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. 156, 42-47 (1996).
42. Kwak, J.-Y. et al. Receptor-mediated activation of murine peritoneal macrophages by antithrombin III acts as a costimulatory signal for nitric oxide synthesis. Cell Immunol. 188, 33-40 (1998).
43. Samlowski, W.E. et al. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J. Immunother. 18, 166-178 (1995).
44. Bishop, D.K. & Orosz, C.G. Limiting dilution analysis for alloreactive, TCGF-secretory T cells Two related LDA methods that discriminate between unstimulated precursor T cells and in vivo-alloactivated T cells. Transplantation 47, 671-677 (1989).